AI Article Synopsis
- The study aimed to examine the types of fungi causing pulmonary infections and the clinical outcomes for affected patients.
- Results indicated that the most common fungi were Aspergillus and Cryptococcus, with higher mortality rates among those with probable infections.
- Antifungal treatment did not show improved outcomes for patients with pulmonary Candida infections, which were relatively rare compared to other fungal infections.
Article Abstract
Objective: To investigate the microbiological spectra and clinical outcome of patients with pulmonary fungal infections.
Methods: All the cases of clinically diagnosed pulmonary fungal infection from January 2002 to June 2006 were reevaluated according to the definitions of European Organization for Research and Treatment of Cancer/National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG), and the etiology of the patients were analyzed.
Results: Pulmonary fungal disease was classified as proven (n = 38), probable (n = 24), possible (n = 35) and colonization (n = 55). In the proven group, the most frequently encountered fungi were Aspergillus species (15/38), followed by Cryptococcus species (13/38), Candida species were rare (2/38). In the probable group, Aspergillus species and Aspergillus species + Candida species were among the most common pathogens; while in the possible group and the colonization group, Candida species were most frequently encountered. The mortality of patients with probable pulmonary fungal infection (58.3%) was higher than that of patients in the possible group (25.7%) or the colonization group (16.4%) (P = 0.001). Univariate analysis showed that only APACHE II score was associated with outcome of patients with "pulmonary Candida infections", and antifungal therapy did not improve the outcome of such patients.
Conclusion: The most frequently encountered fungi in patients with pulmonary fungal infections were Aspergillus species, followed by Cryptococcus species. Primary Candida pulmonary infections were rare.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers.
ACS Infect Dis
January 2025
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Developing new classes of drugs that are active against infections caused by is a priority for treating and managing this deadly disease. Here, we describe screening a small library of 20 DNA gyrase inhibitors and identifying new lead compounds. Three structurally diverse analogues were identified with minimal inhibitory concentrations of 0.
View Article and Find Full Text PDFIdentification of biomarkers associated with ferroptosis in macrophages infected with Mycobacterium abscessus using bioinformatic tools.
PLoS One
January 2025
Department of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Jiao Tong University Medical College, Shanghai, China.
Mycobacterium abscessus is a rapidly growing nontuberculous mycobacterium that causes severe pulmonary infections. Recent studies indicate that ferroptosis may play a critical role in the pathogenesis of M. abscessus pulmonary disease.
View Article and Find Full Text PDFSafety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis.
Clin Infect Dis
January 2025
EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients.
Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics.
The Gut in Critical Illness.
Curr Gastroenterol Rep
December 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Wisconsin, 8701 West Watertown Plank Road, 8th Floor: HUB for Collaborative Medicine, Milwaukee, WI, 53226, USA.
Purpose Of Review: The purpose of this narrative review is to describe the mechanisms for gut dysfunction during critical illness, outline hypotheses of gut-derived inflammation, and identify nutrition and non-nutritional therapies that have direct and indirect effects on preserving both epithelial barrier function and gut microbiota during critical illness.
Recent Findings: Clinical and animal model studies have demonstrated that critical illness pathophysiology and interventions breach epithelial barrier function and convert a normally commensal gut microbiome into a pathobiome. As a result, the gut has been postulated to be the "motor" of critical illness and numerous hypotheses have been put forward to explain how it contributes to systemic inflammation and drives multiple organ failure.
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
Cancer Chemother Pharmacol
January 2025
Institute of Medicine, Chung-Shan Medical University, Taichung, 40201, Taiwan.
Objective: Based on our previous research, which demonstrated that elevated plasma endoglin (ENG) levels in lung cancer patients were associated with a better prognosis, increased sensitivity to pemetrexed, and enhanced tumor suppression, this study aims to validate these findings at the cellular level. The focus is on membrane and extracellular ENG and their influence on drug response and tumor cell behavior in non-small cell lung cancer (NSCLC) cells.
Methods: The correlation between ENG expression and pemetrexed-induced cytotoxicity in eight human non-squamous subtype NSCLC cell lines was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!